All posts by: Michael Zand

About Michael Zand

Synthetic biology’s ‘promise and potential’ capture investor attention – Genetic Literacy Project

Continue reading

2018-05-08 NEWS

Genetic Literacy Project

Synthetic biology’s ‘promise and potential’ capture investor attention
Genetic Literacy Project
Synthetic Biology has become the new frontier of genetic engineering, promising to radically change the way we make clothes, fragrances, flavors, biofuels and plastics. Utilizing yeast, algae, microbes and bacteria as tiny manufacturing plants, it may

Continue reading

2018-05-08 NEWS

Genetic Literacy Project

Synthetic biology’s ‘promise and potential’ capture investor attention
Genetic Literacy Project
Utilizing yeast, algae, microbes and bacteria as tiny manufacturing plants, it may help us produce meatless meat, non-animal leather and even clean up oil spills. We could find our way to greater sustainability by replacing plastics, metals and wood

Continue reading

2018-05-08 NEWS

Positive Newspaper

Stem Cells in Drug Discovery & Toxicity Screening Conference 2018 (San Diego, CA, United States – October 4th-5th …
GlobeNewswire (press release)
Dublin, May 08, 2018 (GLOBE NEWSWIRE) — The “Stem Cells in Drug Discovery & Toxicity Screening 2018″ conference has been added to ResearchAndMarkets.com’s offering. Stem Cells in Drug Discovery, and Toxicity Screening 2018 brings together researchers
Stem Cell Assay Market to Surge at a Robust Pace by 2024Digital Journal
Canine Stem Cell Therapy Market to hike at 4.2% CAGR During 2017-2026Technical Progress

all 6 news articles »

Continue reading

2018-05-08 NEWS

Nationwide Children’s gene therapy spinoff raises up to $105M, with option to be acquired
Columbus Business First
Sarepta Therapeutics Inc. is investing up to $105 million in the latest gene therapy spinoff from Nationwide Children’s Hospital – and signed an option to acquire the company for an undisclosed but higher amount if clinical trial results are promising

and more »

Continue reading

2018-05-08 NEWS

Week Herald

Atara Biotherapeutics Expands T-Cell Immunotherapy Collaboration to Advance Next-Generation CAR T Technologies …
GlobeNewswire (press release)
Entry into genetically engineered T-cells marks next step in Atara’s strategy to advance leadership position in off-the-shelf, allogeneic T-cell immunotherapy. SOUTH SAN FRANCISCO, Calif., May 08, 2018 (GLOBE NEWSWIRE) — Atara Biotherapeutics, Inc
Atara Biotherapeutics, Inc.StreetInsider.com
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)P&T Community
Genentech R&D leader Dietmar Berger moves to Atara Bio, heading up off-the-shelf T cell workEndpoints News

all 45 news articles »